More than the same period, statin use for primary prevention rose from nearly 9 % to about 34 %. We observed a growing trend in statin use in both principal and secondary prevention, but missed that high potency statin make use of was connected with vascular disease, Johansen stated. Secondary prevention refers to treatment in people with vascular disease. The findings were published online Aug. 24 in the journal JAMA Internal Medication.The authors vouch for the accuracy and completeness of the reported data and the fidelity of this report to the trial process and statistical analysis plan, which can be found with the full text of this content at NEJM.org. Data Collection Each patient’s total kidney volume was measured by means of stomach magnetic resonance imaging without the administration of contrast materials at enrollment and six months later . Patients with a documented upsurge in total kidney level of more than 2 percent during this run-in phase were randomly assigned in a 1:1 ratio to receive either sirolimus or standard care . Sufferers with significantly less than a 2 percent increase in total kidney volume underwent a third measurement of kidney volume after a second 6-month period and underwent randomization if the upsurge in total kidney quantity was more than 2 percent during the second run-in phase.